103.15 Financial Toxicity Following Gastrointestinal Oncology Surgery

L. W. Young1, A. Feeley1, P. Awad1, S. Shebrain1, G. Munene1,2  1Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA 2Western Michigan Cancer Center, Kalamazoo, MI, USA

Introduction:  Despite increased recognition of treatment-associated costs (financial toxicity) in oncology, there is limited understanding of the patient and treatment-level characteristics related to financial toxicity in gastrointestinal oncology surgery (GI) patients. Our aim is to identify risk factors for financial toxicity amongst GI patients.

Methods:  This is a single-institution cross-sectional survey of GI patients. Financial toxicity was measured via the Likert-type 11-item comprehensive score for financial toxicity (COST) instrument. Multivariable logistic regression was used to identify patient and treatment factors associated with worsening financial toxicity.

Results: A total of 65 patients were included, 34 (52%) of which were female. Most of the patients underwent pancreatic surgery (n=27, 42.5%). 35 (53.8%) patients reported high levels of financial distress. Higher financial distress was associated with insurance type, emergency department visits and marital status (p<0.05).

Conclusion: In GI patients, specific variables are associated with increased levels of financial toxicity. These variables may prove useful in identifying patients who might benefit from financial navigation interventions.